Parabilis Medicines, Inc.
PBLS evidence brief
What we can confirm
- BioSniper Score:
- 9.9 / 10
- Market Cap:
- $5.16B
What it means
What to watch
Prepared research question
What matters most for PBLS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PBLS
Parabilis Medicines, Inc. (PBLS) is a biotech company advancing a proprietary Helicon™ platform and lead candidate zolucatetide for Wnt/β-catenin-driven diseases, with a strategic collaboration with Regeneron and a cash position of $1,087.1M as of 2026-06-30.
Key risk: No approved products
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$5.16B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial for Parabilis Medicines, Inc..
Parabilis Medicines, Inc. (PBLS) is a biotech company advancing a proprietary Helicon™ platform and lead candidate zolucatetide for Wnt/β-catenin-driven diseases, with a strategic collaboration with Regeneron and a cash position of $1,087.1M as of 2026-06-30.
- Cash & equivalents of $1,087.1M as of 2026-06-30 [sec]
- Total revenue of $0.1M and net income of -$52.5M as of 2026-06-30 [sec]
- Shareholders' equity of $1,047.7M and total debt of $0.1M as of 2026-06-30 [sec]
- Strategic research collaboration with Regeneron to develop Antibody-Helicon Conjugates, with $125M upfront and potential up to $2.2B in milestones plus tiered royalties [news · 2026-08-13]
- Progress toward planned Phase 3 registrational trial in desmoid tumors for zolucatetide [news · 2026-08-13]
What works
- Strong cash position of $1,087.1M as of 2026-06-30 provides substantial runway for R&D and operations [sec]
- Strategic collaboration with Regeneron brings $125M upfront and potential for up to $2.2B in milestones, validating the Helicon™ platform [news · 2026-08-13]
- Advancing zolucatetide toward a Phase 3 registrational trial in desmoid tumors, indicating progress in a defined clinical pathway [news · 2026-08-13]
What to weigh
- Minimal revenue of $0.1M as of 2026-06-30 reflects pre-commercial stage with no approved products [sec]
- Net loss of -$52.5M as of 2026-06-30 indicates ongoing operating expenses exceeding income [sec]
- Dependence on future milestone payments and royalties from the Regeneron collaboration, which are not guaranteed [news · 2026-08-13]
From the filings
Quoted directly from source documents.
Regeneron collaboration details
“received $125M in upfront consideration and equity investment, with the potential for up to $2.2B in milestone payments plus tiered royalties”
News · August 13, 2026
Progress toward Phase 3 trial for zolucatetide
“progress toward planned Phase 3 registrational trial in desmoid tumors”
News · August 13, 2026
Risks & what to watch (3)›
Key risks
- No approved products — Company has minimal revenue ($0.1M as of 2026-06-30) and no marketed drugs, relying on pipeline success [sec]
- Operating losses — Net loss of -$52.5M as of 2026-06-30 indicates ongoing cash burn without product revenue [sec]
- Milestone dependency — Regeneron collaboration milestones up to $2.2B are contingent on development and commercial success [news · 2026-08-13]
What to watch
- Initiation and results of the planned Phase 3 registrational trial for zolucatetide in desmoid tumors [news · 2026-08-13]
- Progress and any milestone achievements under the Regeneron Antibody-Helicon Conjugate collaboration [news · 2026-08-13]
- Cash runway and burn rate given $1,087.1M cash and ongoing net losses [sec]
Sources: Catalysts · Competitor trials · News · Generated October 12, 2026 · How we verify sources →
Run Parabilis Medicines, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Parabilis Medicines, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.12 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
14 buys · 0 sells (180d)
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Parabilis Medicines, Inc.?
Parabilis Medicines, Inc. (PBLS) is a biotech company advancing a proprietary Helicon™ platform and lead candidate zolucatetide for Wnt/β-catenin-driven diseases, with a strategic collaboration with Regeneron and a cash position of $1,087.1M as of 2026-06-30.
Who is the CEO of Parabilis Medicines, Inc.?
Dr. Mathai Mammen M.D., Ph.D. is the chief executive officer of Parabilis Medicines, Inc. (PBLS).
Where is Parabilis Medicines, Inc. headquartered?
Parabilis Medicines, Inc. (PBLS) is headquartered in Cambridge, MA, United States.
What therapeutic areas does Parabilis Medicines, Inc. focus on?
Parabilis Medicines, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.